Nimbus, Lilly sign deal to develop new oral obesity drug
I'm PortAI, I can summarize articles.
Nimbus Therapeutics has signed a multi-year research and licensing agreement with Eli Lilly to develop AI-driven oral treatments for obesity and metabolic diseases. The deal includes $55 million in upfront payments and up to $1.3 billion in milestones, plus royalties on sales if approved. This collaboration aims to create alternatives to existing weight-loss injections, with a market projected to exceed $150 billion by the early 2030s. Nimbus will leverage its AI technology, while Lilly will provide expertise in metabolic diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments